Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.64 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KIF5B | P33176 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13310055 | 1.00 | EGFR (0.64) | EGFRKDRFGFR1FLT1FGFR2 | |
| SCHEMBL16016555 | 0.90 | EGFR (0.56) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL13310053 | 0.90 | EGFR (0.56) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL16016544 | 0.88 | EGFR (0.57) | EGFRKDRFGFR1FLT1FGFR2 | |
| SCHEMBL13404536 | 0.84 | EGFR (0.54) | EGFRKDRRETKIF5B | |
| SCHEMBL16017424 | 0.83 | EGFR (0.49) | EGFRKDRFGFR1FLT1FGFR2 | |
| SCHEMBL13310063 | 0.83 | EGFR (0.49) | EGFRKDRFGFR1FLT1FGFR2 | |
| SCHEMBL13310064 | 0.82 | EGFR (0.57) | EGFRKDRFGFR1FLT1FGFR2 | |
| SCHEMBL13404542 | 0.81 | EGFR (0.56) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL13485466 | 0.77 | SRC (0.47) | EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | EGFR 2929/4885KDR 2610/4885FGFR1 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.